Prevalence of Age-Related Macular Degeneration in Nakuru, Kenya: A Cross-Sectional Population-Based Study

English version České info

Background:
Diseases of the posterior segment of the eye, including age-related macular degeneration (AMD), have recently been recognised as the leading or second leading cause of blindness in several African countries. However, prevalence of AMD alone has not been assessed. We hypothesized that AMD is an important cause of visual impairment among elderly people in Nakuru, Kenya, and therefore sought to assess the prevalence and predictors of AMD in a diverse adult Kenyan population.

Methods and Findings:
In a population-based cross-sectional survey in the Nakuru District of Kenya, 100 clusters of 50 people 50 y of age or older were selected by probability-proportional-to-size sampling between 26 January 2007 and 11 November 2008. Households within clusters were selected through compact segment sampling.

All participants underwent a standardised interview and comprehensive eye examination, including dilated slit lamp examination by an ophthalmologist and digital retinal photography. Images were graded for the presence and severity of AMD lesions following a modified version of the International Classification and Grading System for Age-Related Maculopathy. Comparison was made between slit lamp biomicroscopy (SLB) and photographic grading.

Of 4,381 participants, fundus photographs were gradable for 3,304 persons (75.4%), and SLB was completed for 4,312 (98%). Early and late AMD prevalence were 11.2% and 1.2%, respectively, among participants graded on images. Prevalence of AMD by SLB was 6.7% and 0.7% for early and late AMD, respectively. SLB underdiagnosed AMD relative to photographic grading by a factor of 1.7.

After controlling for age, women had a higher prevalence of early AMD than men (odds ratio 1.5; 95% CI, 1.2–1.9). Overall prevalence rose significantly with each decade of age. We estimate that, in Kenya, 283,900 to 362,800 people 50 y and older have early AMD and 25,200 to 50,500 have late AMD, based on population estimates in 2007.

Conclusions:
AMD is an important cause of visual impairment and blindness in Kenya. Greater availability of low vision services and ophthalmologist training in diagnosis and treatment of AMD would be appropriate next steps.

Please see later in the article for the Editors' Summary

Vyšlo v časopise: Prevalence of Age-Related Macular Degeneration in Nakuru, Kenya: A Cross-Sectional Population-Based Study. PLoS Med 10(2): e32767. doi:10.1371/journal.pmed.1001393
Kategorie: Research Article
prolekare.web.journal.doi_sk: https://doi.org/10.1371/journal.pmed.1001393

Souhrn

Zdroje

1. PascoliniD, MariottiSP (2011) Global estimates of visual impairment: 2010. Br J Ophthalmol 96: 614–618.

2. ResnikoffS, PascoliniD, Etya'aleD, KocurI, PararajasegaramR, et al. (2004) Global data on visual impairment in the year 2002. Bull World Health Organ 82: 844–851.

3. OlsonJH, ErieJC, BakriSJ (2011) Nutritional supplementation and age-related macular degeneration. Semin Ophthalmol 26: 131–136.

4. NgWT, GogginM (2006) Awareness of and compliance with recommended dietary supplement among age-related macular degeneration patients. Clin Exp Ophthalmol 34: 9–14.

5. CruickshanksKJ, KleinR, KleinBE, NondahlDM (2001) Sunlight and the 5-year incidence of early age-related maculopathy: the beaver dam eye study. Arch Ophthalmol 119: 246–250.

6. BuchH (2005) Fourteen-year incidence of age-related maculopathy and cause-specific prevalence of visual impairment and blindness in a Caucasian population: the Copenhagen City Eye Study. Acta Ophthalmol Scand 83: 400–401.

7. BuchH, VindingT, la CourM, JensenGB, PrauseJU, et al. (2005) Risk factors for age-related maculopathy in a 14-year follow-up study: the Copenhagen City Eye Study. Acta Ophthalmol Scand 83: 409–418.

8. ChoudhuryF, VarmaR, McKean-CowdinR, KleinR, AzenSP (2011) Risk factors for four-year incidence and progression of age-related macular degeneration: the Los Angeles Latino Eye Study. Am J Ophthalmol 152: 385–395.

9. ArnarssonA, SverrissonT, StefanssonE, SigurdssonH, SasakiH, et al. (2006) Risk factors for five-year incident age-related macular degeneration: the Reykjavik Eye Study. Am J Ophthalmol 142: 419–428.

10. ChenSJ, ChengCY, PengKL, LiAF, HsuWM, et al. (2008) Prevalence and associated risk factors of age-related macular degeneration in an elderly Chinese population in Taiwan: the Shihpai Eye Study. Invest Ophthalmol Vis Sci 49: 3126–3133.

11. MunozB, KleinR, RodriguezJ, SnyderR, WestSK (2005) Prevalence of age-related macular degeneration in a population-based sample of Hispanic people in Arizona: Proyecto VER. Arch Ophthalmol 123: 1575–1580.

12. VingerlingJR, HofmanA, GrobbeeDE, de JongPT (1996) Age-related macular degeneration and smoking. The Rotterdam Study. Arch Ophthalmol 114: 1193–1196.

13. YasudaM, KiyoharaY, HataY, ArakawaS, YonemotoK, et al. (2009) Nine-year incidence and risk factors for age-related macular degeneration in a defined Japanese population the Hisayama study. Ophthalmology 116: 2135–2140.

14. LeskeMC, WuSY, HymanL, HennisA, NemesureB, et al. (2004) Four-year incidence of macular changes in the Barbados Eye Studies. Ophthalmology 111: 706–711.

15. LeskeMC, WuSY, HonkanenR, NemesureB, SchachatA, et al. (2007) Nine-year incidence of open-angle glaucoma in the Barbados Eye Studies. Ophthalmology 114: 1058–1064.

16. OyeJE, KuperH (2007) Prevalence and causes of blindness and visual impairment in Limbe urban area, South West Province, Cameroon. Br J Ophthalmol 91: 1435–1439.

17. HabiyakireC, KabonaG, CourtrightP, LewallenS (2010) Rapid assessment of avoidable blindness and cataract surgical services in kilimanjaro region, Tanzania. Ophthalmic Epidemiol 17: 90–94.

18. MathengeW, KuperH, LimburgH, PolackS, OnyangoO, et al. (2007) Rapid assessment of avoidable blindness in Nakuru district, Kenya. Ophthalmology 114: 599–605.

19. MathengeW, NkurikiyeJ, LimburgH, KuperH (2007) Rapid assessment of avoidable blindness in Western Rwanda: blindness in a postconflict setting. PLoS Med 4: e217 doi:10.1371/journal.pmed.0040217.

20. KikiraS (2007) RAAB survey of Pemba and Unguja islands, Zanzibar. Community Eye Health 20: 71.

21. MoserCL, Martin-BaraneraM, VegaF, DraperV, GutierrezJ, et al. (2002) Survey of blindness and visual impairment in Bioko, Equatorial Guinea. Br J Ophthalmol 86: 257–260.

22. SommerA, TielschJM, KatzJ, QuigleyHA, GottschJD, et al. (1991) Racial differences in the cause-specific prevalence of blindness in east Baltimore. New Engl J Med 325: 1412–1417.

23. Kenya National Bureau of Statistics (2010) Kenya 2009 population and housing census highlights. Nairobi: Kenya National Bureau of Statistics.

24. TurnerAG, MagnaniRJ, ShuaibM (1996) A not quite as quick but much cleaner alternative to the Expanded Programme on Immunization (EPI) Cluster Survey design. Int J Epidemiol 25: 198–203.

25. RosserDA, LaidlawDA, MurdochIE (2001) The development of a “reduced logMAR” visual acuity chart for use in routine clinical practice. Br J Ophthalmol 85: 432–436.

26. DineenB, GilbertCE, RabiuM, KyariF, MahdiAM, et al. (2008) The Nigerian national blindness and visual impairment survey: rationale, objectives and detailed methodology. BMC Ophthalmol 8: 17.

27. BirdAC, BresslerNM, BresslerSB, ChisholmIH, CoscasG, et al. (1995) An international classification and grading system for age-related maculopathy and age-related macular degeneration. The International ARM Epidemiological Study Group. Surv Ophthalmol 39: 367–374.

28. KuperH, PolackS, EusebioC, MathengeW, WadudZ, et al. (2008) A case-control study to assess the relationship between poverty and visual impairment from cataract in Kenya, the Philippines, and Bangladesh. PLoS Med 5: e244 doi:10.1371/journal.pmed.0050244.

29. PolackS, KuperH, MathengeW, FletcherA, FosterA (2007) Cataract visual impairment and quality of life in a Kenyan population. Br J Ophthalmol 91: 927–932.

30. MathengeW, BastawrousA, FosterA, KuperH (2012) The Nakuru posterior segment eye disease study: methods and prevalence of blindness and visual impairment in Nakuru, Kenya. Ophthalmology 119: 2033–2039.

31. GregorZ, JoffeL (1978) Senile macular changes in the black African. Br J Ophthalmol 62: 547–550.

32. SchachatAP, HymanL, LeskeMC, ConnellAM, WuSY (1995) Features of age-related macular degeneration in a black population. The Barbados Eye Study Group. Arch Ophthalmol 113: 728–735.

33. WuLH (1987) Study of aging macular degeneration in China. Jpn J Ophthalmol 31: 349–367.

34. VarmaR, Fraser-BellS, TanS, KleinR, AzenSP (2004) Prevalence of age-related macular degeneration in Latinos: the Los Angeles Latino eye study. Ophthalmology 111: 1288–1297.

35. NirmalanPK, KatzJ, RobinAL, TielschJM, NamperumalsamyP, et al. (2004) Prevalence of vitreoretinal disorders in a rural population of southern India: the Aravind Comprehensive Eye Study. Arch Ophthalmol 122: 581–586.

36. GuptaSK, MurthyGV, MorrisonN, PriceGM, DheraniM, et al. (2007) Prevalence of early and late age-related macular degeneration in a rural population in northern India: the INDEYE feasibility study. Invest Ophthalmol Vis Sci 48: 1007–1011.

37. VingerlingJR, DielemansI, HofmanA, GrobbeeDE, HijmeringM, et al. (1995) The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 102: 205–210.

38. BjornssonOM, SyrdalenP, BirdAC, PetoT, KingeB (2006) The prevalence of age-related maculopathy (ARM) in an urban Norwegian population: the Oslo Macular study. Acta Ophthalmol Scand 84: 636–641.

39. KleinR, KleinBE, MossSE (1992) Diabetes, hyperglycemia, and age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 99: 1527–1534.

40. PieramiciDJ, BresslerNM, BresslerSB, SchachatAP (1994) Choroidal neovascularization in black patients. Arch Ophthalmol 112: 1043–1046.

41. FriedmanDS, KatzJ, BresslerNM, RahmaniB, TielschJM (1999) Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology 106: 1049–1055.

42. Goatman K, Whitwam AD, Manivannan A, Olson JA, Sharp PF (2003) Colour normalisation of retinal images. Aberdeen: University of Aberdeen Department of Bio-Medical Physics and Bio-Engineering. Available: http://www.biomed.abdn.ac.uk/Abstracts/A01128/. Accessed 16 January 2013.

43. Wolf-SchnurrbuschUEK, RoosliN, WeyermannE, HeldnerMR, HohneK, et al. (2007) Ethnic differences in macular pigment density and distribution. Invest Ophthalmol Vis Sci 48: 3783–3787.

44. HubschmanJP, ReddyS, SchwartzSD (2009) Age-related macular degeneration: experimental and emerging treatments. Clin Ophthalmol 3: 167–174.

45. MartinDF, MaguireMG, YingGS, GrunwaldJE, FineSL, et al. (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. New Engl J Med 364: 1897–1908.

46. MartinDF, MaguireMG, FineSL, YingGS, JaffeGJ, et al. (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119: 1388–1398.

47. ChakravarthyU, HardingSP, RogersCA, DownesSM, LoteryAJ, et al. (2012) Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 119: 1399–1411.

48. World Health Organization Regional Office for Africa (2009) VID report: blindness and deafness prevention. Geneva: World Health Organization.